Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maoliang Xiao"'
Autor:
Xingxiang Pu, Gen Lin, Maoliang Xiao, Jie Lin, Qianzhi Wang, Yi Kong, Xuejun Yan, Fang Xu, Yan Xu, Jia Li, Kang Li, Bolin Chen, Xiaoping Wen, Yali Tan, Fengzhuo Cheng, Kangle Zhu, Na Li, Lin Wu
Publikováno v:
EClinicalMedicine, Vol 67, Iss , Pp 102403- (2024)
Summary: Background: Platinum-doublet chemotherapy plus immunotherapy has been the standard of care for the first-line treatment of advanced non-small cell lung cancer lacking actional driver mutations. However, optimization of drug combinations is s
Externí odkaz:
https://doaj.org/article/bd7cf6b86de74344ba804c838845cf40
Autor:
Qitong Chen, Dengjie Ouyang, Munawar Anwar, Ning Xie, Shouman Wang, Peizhi Fan, Liyuan Qian, Gannong Chen, Enxiang Zhou, Lei Guo, Xiaowen Gu, Boni Ding, Xiaohong Yang, Liping Liu, Chao Deng, Zhi Xiao, Jing Li, Yunqi Wang, Shan Zeng, Jinhui Hu, Wei Zhou, Bo Qiu, Zhongming Wang, Jie Weng, Mingwen Liu, Yi Li, Tiegang Tang, Jianguo Wang, Hui Zhang, Bin Dai, Wuping Tang, Tao Wu, Maoliang Xiao, Xiantao Li, Hailong Liu, Lai Li, Wenjun Yi, Quchang Ouyang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Externí odkaz:
https://doaj.org/article/8f47dfb6ab9a465cb3239f122ee82323
Autor:
Qitong Chen, Dengjie Ouyang, Munawar Anwar, Ning Xie, Shouman Wang, Peizhi Fan, Liyuan Qian, Gannong Chen, Enxiang Zhou, Lei Guo, Xiaowen Gu, Boni Ding, Xiaohong Yang, Liping Liu, Chao Deng, Zhi Xiao, Jing Li, Yunqi Wang, Shan Zeng, Jinhui Hu, Wei Zhou, Bo Qiu, Zhongming Wang, Jie Weng, Mingwen Liu, Yi Li, Tiegang Tang, Jianguo Wang, Hui Zhang, Bin Dai, Wuping Tang, Tao Wu, Maoliang Xiao, Xiantao Li, Hailong Liu, Lai Li, Wenjun Yi, Quchang Ouyang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Pyrotinib, an irreversible pan-ERBB inhibitor, has shown promising antitumour activity, and acceptable tolerability. This research was conducted to evaluate the actual use and effectiveness of pyrotinib in China, therefore, contributed to
Externí odkaz:
https://doaj.org/article/e32a29a0bdc949c79ff4238792b3eb43
Autor:
Wuping Tang, Yi Li, Wei Zhou, Jinhui Hu, Bin Dai, Liyuan Qian, Hui Zhang, Zhi Xiao, Jianguo Wang, Tao Wu, Shouman Wang, Yunqi Wang, Q. Chen, Tiegang Tang, Xiaohong Yang, Jie Weng, Munawar Anwar, Dengjie Ouyang, Liping Liu, Peizhi Fan, Ning Xie, Maoliang Xiao, Xiaowen Gu, Jing Li, Bo Qiu, Zhongming Wang, Quchang Ouyang, Shan Zeng, Enxiang Zhou, Wenjun Yi, Chao Deng, Hailong Liu, Xiantao Li, Boning Ding, Lai Li, Lei Guo, Mingwen Liu, Gannong Chen
Publikováno v:
Clinical Cancer Research. 27:4634-4641
Purpose: Patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have poor prognoses. Pyrotinib has shown promising antitumor activity in MBC to improve progression-free survival (PFS). However, findings based on real-world data to analyze
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b73630544b5d4411c573438ef0dd25d
https://doi.org/10.1158/1078-0432.ccr-21-0474
https://doi.org/10.1158/1078-0432.ccr-21-0474
Autor:
Lin Wu, Xingxiang Pu, Gen Lin, Maoliang Xiao, Jie Lin, Qianzhi Wang, Yi Kong, Xuejun Yan, Fang Xu, Yan Xu, Jia Li, Kang Li, bolin chen, Xiaoping Wen, Yali Tan
Publikováno v:
Journal of Clinical Oncology. 40:9034-9034
9034 Background: Cytotoxic chemotherapy and anti-angiogenic therapy may enhance the therapeutic efficacy of immune checkpoint inhibitors (ICIs). Platinum-containing dual-agent chemotherapy combined with ICIs is the standard first-line treatment for n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09d9deb6ffa8124ce26c3d206e7e4a0f
https://doi.org/10.1200/jco.2022.40.16_suppl.9034
https://doi.org/10.1200/jco.2022.40.16_suppl.9034
Autor:
Maoliang Xiao, Zemin Xiao, Peiguo Cao, Kang Li, Jie Weng, Zhongsha Ma, Xingxiang Pu, Y. Chen, Zhijun Wu, Huaxin Duan, Lin Wu, Yan Xu, Q. Wang, Jia Li, Yongqing Cao, Hui Zhang
Publikováno v:
Journal of Clinical Oncology. 39:e21186-e21186
e21186 Background: Docetaxel is one of the standard second-line treatments for advanced non-small cell lung cancer (NSCLC), but the effect is limited. The combination of docetaxel and antiangiogenic drug (ramucirumab/nintedanib) has demonstrated anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24038f7ef89e80a2b7990dfc11f0b68e
https://doi.org/10.1200/jco.2021.39.15_suppl.e21186
https://doi.org/10.1200/jco.2021.39.15_suppl.e21186
Autor:
Q. Wang, Zhongsha Ma, Zhijun Wu, Hui Zhang, Jia Li, Yan Xu, Jie Weng, Maoliang Xiao, Y. Chen, Zemin Xiao, Yongqing Cao, Kang Li, Xingxiang Pu, Lin Wu, Huaxin Duan, Peiguo Cao
Publikováno v:
Journal of Clinical Oncology. 38:e21703-e21703
e21703 Background: Anlotinib is an oral VEGFR, FGFR, PDGFR and c-Kit tyrosine kinase inhibitor, which can prolong both PFS and OS of refractory advanced NSCLC patients in phase III trial: ALTER0303. The combination of docetaxel and ramucirumab/ninted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::804da3a5864c29d209c52106c33cbc85
https://doi.org/10.1200/jco.2020.38.15_suppl.e21703
https://doi.org/10.1200/jco.2020.38.15_suppl.e21703